|Synonyms:||GS-7977;N-[[P(S),2'R]-2'-Deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-L-alanine 1-methylethyl ester;PSI 7977;sofosbuvir;GS-7977/sofosbuvir;sofosbuvir, PSI7977;(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-Methyltetrahydrofuran-2-yl)Methoxy)(phenoxy)phosphoryl)aMino)propanoate;PSI-7977 Discontinued|
|Product Categories:||PSI7977;Pharmaceutical intermediate;API;Inhibitors;Liver Disease Series|
|Sofosbuvir Chemical Properties|
|Sofosbuvir Usage And Synthesis|
|Oral drug for hepatitis c||Sofosbuvir is also called sovaldi, is the world's first oral drug for hepatitis c, was approved one of the most important new drugs in the United States in 2013. When used in a specific therapy for chronic hepatitis c genotype, it can eliminate the traditional injection drug interferon (IFN) in demand, successful developed by the world's largest manufacturer of anti-hiv drugs - gilead sciences company in the United States, its English name is Sofosbuvir, Sovaldi, its global sales peak might exceed $10 billion. |
On December 6, 2013, the United States food and drug administration (FDA) approved sofosbuvir (Sovaldi) for the treatment of chronic hepatitis c virus (HCV) infection. Sofosbuvir is first used in the treatment of certain types of HCV infection without the need for safe and effective drugs at the same time the use of interferon.
Hepatitis c is a viral disease that can cause inflammation of the liver, cause liver function abate or liver failure. Most of the patients with HCV infection until liver damage becomes more obvious symptoms, this process may take several years. Some chronic HCV infection, many years later, there will be a scar and cirrhosis of the liver and can cause bleeding, jaundice (eyes or skin yellow), liver ascites, complications such as infection or liver cancer. According to the centers for disease control and prevention of information, about 3.2 million Americans have hepatitis c virus (HCV) infection.
Sofosbuvir is a kind of nucleotide analogue inhibitors, it can block a specific protein, which is required for the hepatitis c virus replication. Sofosbuvir is used as an antiviral combined treatment of chronic HCV infection. There are several different types of HCV infection. Based on the type of patients with HCV infection, treatment may include sofosbuvir, ribavirin or SuoFei wei and polyethylene glycol α. Ribavirin and polyethylene glycol α are also used for the treatment of HCV infection of two drugs.
Sofosbuvir is the third breakthrough treatment qualification awarded by the FDA approved drugs. If the preliminary clinical research evidence to prove that a drugs can provide patients with serious or life-threatening disease with a substantial improvement compared with the existing treatment, so the drug is the sponsor for the drug applied to the FDA for breakthrough treatments.
The United States patent validity: on March 26, 2029 (US patent no.:7964580 and 8334270), April 3, 2025 (US patent no. :7429572 and 8415322).
The above information is compiled by Chemicalbook XiaoNan .
|Usage||PSI-7977 is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the t
reatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.|
|Sofosbuvir Preparation Products And Raw materials|